Drug
Ak104 Anlotinib
Ak104 Anlotinib: highest development phase Phase 1/2, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK104+anlotinib NCT04646330 | Phase 1/2 | NSCLC |
Latest
No recent events.
Follow Ak104 Anlotinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.